CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting

Xinyuan Liu; Juanjuan Zhao; Xiangqian Guo; Yongping Song

doi:10.1186/s13045-023-01488-4

CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting

J Hematol Oncol. 2023 Aug 3;16(1):90. doi: 10.1186/s13045-023-01488-4.

Authors

Xinyuan Liu^#¹, Juanjuan Zhao^#², Xiangqian Guo¹, Yongping Song³

Affiliations

¹ Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, School of Basic Medical Sciences, Henan University, Kaifeng, 475004, Henan, China.
² Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
³ Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China. songyp@zzu.edu.cn.

^# Contributed equally.

Abstract

Multiple bispecific antibodies (bsAbs) have been approved for cancer immunotherapy. Several CD20 × CD3 bsAbs have demonstrated significant anti-B-cell non-Hodgkin lymphoma (NHL) activity by engaging T cells to target CD20⁺ NHL cells in clinical trials. Mosunetuzumab, epcoritamab and glofitamab have been approved recently for B-cell NHL therapy. In this study, we summarized several latest reports on CD20 × CD3 bsAbs for the therapy of B-cell NHL from the ASCO 2023 annual meeting (ASCO2023).

Keywords: Bispecific antibody; CD20; CD3; EPCORE NHL-1; Non-Hodgkin's lymphoma.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Bispecific* / therapeutic use
Antibodies, Monoclonal / therapeutic use
Antigens, CD20
Antineoplastic Agents* / therapeutic use
Humans
Lymphoma* / drug therapy
Lymphoma, B-Cell*

Substances

glofitamab
Antibodies, Bispecific
Antibodies, Monoclonal
Antigens, CD20
Antineoplastic Agents